COMMUNIQUÉS West-GlobeNewswire

Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
07/01/2026
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study in CSU and CIndU [...]
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
07/01/2026
LOUISVILLE, Ky., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as limited distribution specialty pharmacy partner for [...]
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
07/01/2026
AUDUBON, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth quarter and full year [...]
Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Abivax Provides 2026 Corporate Outlook
07/01/2026
Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space [...]
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
07/01/2026
Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn [...]
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
07/01/2026
Decision ensures continued patient access to VENDAJE ® and VENDAJE AC ® POMPANO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development [...]
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
07/01/2026
FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
07/01/2026
Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will [...]
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
07/01/2026
NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this [...]
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra [...]
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing [...]
Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
07/01/2026
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Décembre 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/01/2026
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
300 Exceptional Teen Scientists Recognized for Innovative STEM Research in Nation’s Oldest and Most Prestigious High School Competition
07/01/2026
Regeneron Science Talent Search Marks Milestone 85th Year with $1.2 Million Awarded to Nation’s Most Promising Young Scientists and Their Schools WASHINGTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Society for Science (the [...]
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
07/01/2026
PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA The combination [...]
AB Science annonce un quatrième cas consécutif de réponse avec la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute, sur la base des données de phase 1
07/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE UN QUATRIÈME CAS CONSÉCUTIF DE RÉPONSE AVEC LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE, SUR LA BASE DES [...]

Pages